Hostname: page-component-cb9f654ff-rkzlw Total loading time: 0 Render date: 2025-08-04T09:36:18.226Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial: commentary, author response

Published online by Cambridge University Press:  27 May 2025

Colleen Loo Open the ORCID record for Colleen Loo [Opens in a new window] ,
Angelo Alonzo ,
David Barton ,
Michael Berk ,
Mary Lou Chatterton Open the ORCID record for Mary Lou Chatterton [Opens in a new window] ,
Vanessa Dong ,
Veronica Gálvez ,
Natalie T. Mills Open the ORCID record for Natalie T. Mills [Opens in a new window] ,
Philip B. Mitchell Open the ORCID record for Philip B. Mitchell [Opens in a new window]  and
Shanthi Sarma
...Show all authors
Colleen Loo*
Affiliation:
Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, New South Wales, Australia; Black Dog Institute, Randwick, New South Wales, Australia; and George Institute for Global Health, Newtown, New South Wales, Australia
Angelo Alonzo
Affiliation:
Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, New South Wales, Australia; Black Dog Institute, Randwick, New South Wales, Australia; and The George Institute for Global Health, Barangaroo, New South Wales, Australia
David Barton
Affiliation:
Neurocentrix, South Carlton, Victoria, Australia
Michael Berk
Affiliation:
Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Barwon Health, Deakin University, Geelong, Australia
Mary Lou Chatterton
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Vanessa Dong
Affiliation:
Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, New South Wales, Australia; and Black Dog Institute, Randwick, New South Wales, Australia
Veronica Gálvez
Affiliation:
Department of Psychiatry and Mental Health, Hospital Universitari Parc Tauli, Sabadell, Spain; and Institut Investigacio I Innovacio Parc Tauli, Sabadell, Spain
Natalie T. Mills
Affiliation:
Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia
Philip B. Mitchell
Affiliation:
Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, New South Wales, Australia
Shanthi Sarma
Affiliation:
Mental Health and Specialist Services, Gold Coast Health, Bond University, Robina, Queensland, Australia
Andrew A. Somogyi
Affiliation:
Discipline of Pharmacology, School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia
Anthony Rodgers
Affiliation:
George Institute for Global Health, Barangaroo, New South Wales, Australia
*
Correspondence: Colleen Loo. Email: colleen.loo@unsw.edu.au
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Ketamine/esketaminemajor depressive disorderclinical drug studiesneuroscienceaffective disorders

Information

Type
Commentary
Information
The British Journal of Psychiatry , Volume 226 , Issue 5 , May 2025 , pp. 317 - 318
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Joks, G, Su, S, King, J. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, joks et al.. Br J Psychiatry 2024 (https://resolve.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/abs/efficacy-and-safety-of-a-4week-course-of-repeated-subcutaneous-ketamine-injections-for-treatmentresistant-depression-kads-study-commentary-joks-et-al/ECA661E0DB69EA284F9776A794244726).CrossRefGoogle ScholarPubMed
Loo, C, Glozier, N, Barton, D, Baune, BT, Mills, NT, Fitzgerald, P, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry 2023; 223: 533–41.CrossRefGoogle ScholarPubMed
UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361: 799–808.CrossRefGoogle Scholar
Rodgers, A, Bahceci, D, Davey, CG, Chatterton, ML, Glozier, N, Hopwood, M, et al. Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression. Aust N Z J Psychiatry 2024; 58: 109–16.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.